Granza Bio is a biotechnology company developing a novel delivery "shell" platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system's powerful suite of weapons, "attack particles". Utilizing their advanced delivery platform, they aim to target these "attack particles" against a range of diseases such as cancer, autoimmune disorders, and infections.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Ashwin Nandakumar

Chief Scientific Officer

Ashwin Jainarayanan

Browse more venture capital transactions:

Prev: 7/4/2024: FreeBnk venture capital transaction
Next: 7/4/2024: Roboat venture capital transaction

Share this article

Where The Data Comes From

We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary